Menu
Back to Journals » OncoTargets and Therapy » Volume 9
Original Research
A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 9,302 | Dovepress* | 8,383+ | 946 | 9,329 | |
| PubMed Central* | 919 | 227 | 1,146 | ||
| Totals | 9,302 | 1,173 | 10,475 | ||
| *Since 30 November 2016 | |||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 3 | 0 | 0 | 1 | 0 | 2 |
View citations on PubMed Central and Google Scholar